Nycomed US has unveiled a new leadership structure.
The new standalone corporation has appointed Brian Markinson as President, CEO and member of the Board, Jeff Bailey as the Chief Operating Officer, and John Golubieski as Chief Financial Officer.
Hakan Bjorklund, Chief CEO of Nycomed and Chairman of the Board of Nycomed US, says the trio will “add to the depth we have within Nycomed US”.
The corporation has been created following the acquisition of Nycomed A/S by Takeda Pharmaceuticals.
The trio have already spent a number of years working together at King Pharmaceuticals.
Prior to working at King, Mr Markinson held senior leadership positions at Bristol-Myers Squibb. He also serves on the Board of a number of other organisations.
“I am delighted, along with Jeff and John, to join the team at Nycomed US,” said the new President. “This is an exciting time for the company because we have the opportunity to grow aggressively and forge our future as an independent entity.
“Jeff and John are great additions to an already strong and focused management team and I am confident we can leverage the Company’s financial strength and unique platform within the dermatology market to drive further growth in our business.”